Last reviewed · How we verify

NCT05848063

Effects of Global Hip Versus Isolated Abductors Strengthening Exercises in Patients Withsecondary Piriformis Syndrome

Completed NA Last updated 18 September 2023
What this trial tests

NA trial testing Global hip muscles strengthening exercises in Piriformis Syndrome in 24 participants. Completed in 25 August 2023.

Timeline
15 March 2023
Primary endpoint
5 August 2023
25 August 2023

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment24
Start date15 March 2023
Primary completion5 August 2023
Estimated completion25 August 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 20 to 50, any sex, with Piriformis Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be a randomized controlled trial. Twenty-four subjects will be assigned randomly by using the lottery method into two groups. Group A will be given a hot pack in addition to the global hip muscles strengthening exercise while group B is the control group which will receive a hot pack in addition to hip abductor strengthening. The time duration will be 6 weeks. Pain intensity will be assessed by NPRS.3 sessions per week will be given for 6 weeks. Outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Piriformis Syndrome

Currently open trials in the same condition.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05848063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing